15. (Original) The composition of claim 1, wherein the complex has a half-life ranging from about 15 minutes to about 1 hour in the presence of supra physiological levels of biotin and an affinity constant ranging from about 1.0 to about 100.0 nanomolar.

20. (Original) The composition of claim 1, wherein the anti-biotin antibody comprises a therapeutic agent that is a cytotoxic agent.

21. (Original) The composition of claim 1, wherein the anti-biotin antibody comprises a diagnostic agent attached thereto.

22. (Original) The composition of claim 1, wherein the anti-biotin antibody has a dual specificity.

23. (Original) The composition of claim 22, wherein the anti-biotin antibody selectively binds to a tumor cell associated antigen.

24. (Original) The composition of claim 22, wherein the anti-biotin antibody selectively binds to a viral associated antigen.

34. (Previously Presented) A composition comprising:

(a) a biotin conjugate comprising

(i) a biotin covalently coupled to

(ii) a chemokine having a pharmacological activity; and

(b) a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is suitable for parenteral administration.

41. (Previously Presented) The composition of claim 1, wherein the composition is lyophilized.

42. (Previously Presented) The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

43. (Previously Presented) The composition of claim 42, wherein the pharmaceutically acceptable carrier is acceptable for a mode of delivery selected from the group consisting of: intradermal delivery, intramuscular delivery, intraperitoneal delivery, intravenous delivery, subcutaneous delivery, and controlled release delivery.

44. (Previously Presented) The composition of claim 1, wherein the biotin is selected from the group consisting of L-biotin, D-biotin and derivative thereof.

45. (Previously Presented) The composition of claim 1, wherein the chemokine is selected from the group consisting of the chemokines of Table 1.

46. (Previously Presented) The composition of claim 1, wherein the chemokine has a carboxyl terminus and the biotin is covalent attached to the carboxyl terminus of the chemokine.

47. (Previously Presented) The composition of claim 1, wherein the biotin is covalently coupled to the pharmacologically active chemokine via a linker molecule.

48. (Previously Presented) The composition of claim 1, wherein the complex has a half-life ranging from about 15 minutes to about 1 hour in the presence of supra physiological levels of biotin.

49. (Previously Presented) The composition of claim 1, wherein the anti-biotin antibody has an affinity constant ranging from about 1.0 to about 100.0 nanomolar.

50. (Previously Presented) The composition of claim 1, wherein the anti-biotin antibody is selected from the group consisting of an intact antibody, and an antibody fragment.

51. (Previously Presented) The composition of claim 1, wherein the anti-biotin antibody is a human antibody or fragment thereof.

52. (Previously Presented) The composition of claim 1, wherein the anti-biotin antibody has a subclass selected from the group consisting of a IgG1 subclass, and an IgG3 subclass.

53. (Previously Presented) The composition of claim 1, wherein the anti-biotin antibody comprises a therapeutic agent attached thereto.

54. (Previously Presented) The composition of claim 1, wherein the complex has a half-life of from one day to one month in vivo.

55. (Previously Presented) The composition of claim 1, wherein the complex has a half-life of from one week to two weeks in vivo.

59. (New) The composition of claim 34, wherein the pharmacologically active chemokine has an agonist activity.

60. (New) The composition of claim 34, wherein the pharmacologically active chemokine has an antagonist activity.

61.(New) The composition of claim 34, wherein the composition is lyophilized.